Johnson & Johnson $JNJ Stock Holdings Lifted by West Michigan Advisors LLC

West Michigan Advisors LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 38.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,054 shares of the company’s stock after acquiring an additional 1,976 shares during the period. West Michigan Advisors LLC’s holdings in Johnson & Johnson were worth $1,077,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Kathleen S. Wright Associates Inc. grew its position in Johnson & Johnson by 3.1% during the second quarter. Kathleen S. Wright Associates Inc. now owns 7,500 shares of the company’s stock valued at $1,225,000 after purchasing an additional 227 shares in the last quarter. Moloney Securities Asset Management LLC grew its position in Johnson & Johnson by 4.2% during the second quarter. Moloney Securities Asset Management LLC now owns 37,079 shares of the company’s stock valued at $5,664,000 after purchasing an additional 1,510 shares in the last quarter. Opus Capital Group LLC grew its position in Johnson & Johnson by 9.9% in the second quarter. Opus Capital Group LLC now owns 6,016 shares of the company’s stock worth $919,000 after acquiring an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in Johnson & Johnson by 45,933.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 1,381 shares of the company’s stock worth $211,000 after acquiring an additional 1,378 shares in the last quarter. Finally, AlTi Global Inc. grew its position in Johnson & Johnson by 2.5% in the second quarter. AlTi Global Inc. now owns 94,274 shares of the company’s stock worth $14,477,000 after acquiring an additional 2,280 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on JNJ shares. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Argus set a $210.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Bank of America boosted their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday. Finally, HSBC boosted their price objective on shares of Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $190.38 on Friday. The stock has a market cap of $458.69 billion, a P/E ratio of 18.38, a PEG ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The company has a fifty day moving average price of $182.26 and a 200 day moving average price of $166.13. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.